Press Releases2019-02-14T10:57:14-06:00

Press Releases

ELIAS Animal Health Adds Clinical Trial Site for ECI™ for the Treatment of Canine Osteosarcoma

ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, is offering a fourth site for its clinical trial to determine the safety and efficacy of ELIAS Cancer Immunotherapy (ECI™) as a treatment for newly- diagnosed appendicular osteosarcoma in dogs. The objective of this clinical trial is to determine whether ECI™ used in combination with surgery produces better outcomes than treatment with surgery alone. Efficacy will be determined by patient survival and comparing the outcomes to historical control data. The trial will be conducted at the Veterinary Specialty Hospital of San Diego. ELIAS Animal [...]

November 15th, 2016|

ELIAS Animal Health Announces First Patient Enrolled in Clinical Trial for ECI™ for the Treatment of Canine B-Cell Lymphoma

Olathe, Kan., Aug. 24, 2016 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a clinical trial to determine the safety and efficacy of ELIAS Cancer Immunotherapy (ECI™), as a treatment for B-cell lymphoma in dogs. The majority of canine lymphomas are derived from B cells. While lymphoma is one of the most responsive cancers to chemotherapy, permanent cures in dogs are extremely rare and remissions are short-lived. There is a need for safer, more effective treatments for this disease. The objective of this clinical trial is [...]

August 24th, 2016|

ELIAS Animal Health Names Ronald Schultz and Noe Reyes to Scientific Advisory Board

Olathe, Kan., September 1, 2015 - ELIAS Animal Health, a clinical stage development company advancing novel targeted T cell-based immunotherapy for the treatment of cancer in companion animals, today announced it has filled the remaining appointments to the company’s scientific advisory board with the additions of Ronald Schultz, PhD, and Noe Reyes, DVM. They join board chair Kevin Schultz, DVM, PhD, and Ralph Richardson, DVM, on the advisory board, which is tasked with offering strategic guidance on the advancement of therapies in development and exploring new therapeutic areas in which the company’s technology would be applicable. Dr. Ron Schultz is [...]

September 1st, 2015|